|
1
|
Pelosi G, Fabbri A, Tamborini E, Perrone
F, Testi AM, Settanni G, Busico A, Centonze G, Braidotti P,
Bulfamante G, et al: Challenging lung carcinoma with coexistent
ΔNp63/p40 and thyroid transcription factor-1 labeling within the
same individual tumor cells. J Thorac Oncol. 10:1500–1502. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hayashi T, Takamochi K, Yanai Y, Mitani K,
Tomita H, Mogushi K, Suehara Y, Takahashi F, Suzuki K, Saito T and
Yao T: Non-small cell lung carcinoma with diffuse coexpression of
thyroid transcription factor-1 and ΔNp63/p40. Hum Pathol.
78:177–181. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Spinelli M, Khorshad J and Viola P: When
tumor doesn't read textbook. Third case of TTF1 and p40
co-expression in the same tumour cells in a non-small cell
carcinoma. A potential new entity to consider? Pathologica.
111:58–61. 2019.PubMed/NCBI
|
|
4
|
Pelosi G, Bulloni M, Martina Vescio M,
Uccella S, Forest F, Leone G, Barberis M, Rahal D, Bossi P, Finzi
G, et al: Coexpression of ΔNp63/p40 and TTF1 within most of the
same individual cells identifies life threatening NSCLC featuring
squamous and glandular biphenotypic differentiation:
Clinicopathologic correlations. JTO Clin Res Rep.
2:1002222021.PubMed/NCBI
|
|
5
|
Chen B and Cheng N: Coexpression of
thyroid transcription factor 1 and P40 in non-small cell lung
cancer cells: A case report. Chin J Pathol. 51:558–560. 2022.(In
Chinese).
|
|
6
|
WHO Classification of Tumours Editorial
Board, . WHO classification of tumours. Thoracic Tumours. 5th
edition. IARC Press; Lyon: 2021
|
|
7
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shi Y, Au JSK, Thongprasert S, Srinivasan
S, Tsai CM, Khoa MT, Heeroma K, Itoh Y, Cornelio G and Yang PC: A
prospective, molecular epidemiology study of EGFR mutations in
Asian patients with advanced non-small-cell lung cancer of
adenocarcinoma histology (PIONEER). J Thorac Oncol. 9:154–162.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pillai RN and Ramalingam SS: The biology
and clinical features of non-small cell lung cancers with EML4-ALK
translocation. Curr Oncol Rep. 14:105–110. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Samuels Y, Wang Z, Bardelli A, Silliman N,
Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, et al:
High frequency of mutations of the PIK3CA gene in human cancers.
Science. 304:5542004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Parra HS, Cavina R, Latteri F, Zucali PA,
Campagnoli E, Morenghi E, Grimaldi GC, Roncalli M and Santoro A:
Analysis of epidermal growth factor receptor expression as a
predictive factor for response to gefitinib (‘Iressa’, ZD1839) in
non-small-cell lung cancer. Br J Cancer. 91:208–212. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dalle S, Poulalhon N and Thomas L:
Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med.
365:1448–1449. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri
S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG and Ladanyi M:
Prevalence, clinicopathologic associations, and molecular spectrum
of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Clin Cancer Res. 18:4910–4918. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Benvenuti S, Sartore-Bianchi A, Di
Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S and Bardelli
A: Oncogenic activation of the RAS/RAF signaling pathway impairs
the response of metastatic colorectal cancers to anti-epidermal
growth factor receptor antibody therapies. Cancer Res.
67:2643–2648. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Schwab R, Petak I, Kollar M, Pinter F,
Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D,
Kopper L and Urban L: Major partial response to crizotinib, a dual
MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient
with de novo c-MET amplification in the absence of ALK
rearrangement. Lung Cancer. 83:109–111. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shaw AT and Solomon BJ: Crizotinib in
ROS1-rearranged non-small-cell lung cancer. N Engl J Med.
372:683–684. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Dumaz N: Mechanism of RAF isoform
switching induced by oncogenic RAS in melanoma. Small GTPases.
2:289–292. 2011. View Article : Google Scholar : PubMed/NCBI
|
